Activin receptor, type-2B Protein

ACVR2B Protein Price Information

ACVR2B Protein Product Information

A DNA sequence encoding the extracellular domain of human ACVR2B (NP_001097.2 ) (Met 1- Thr 134) was fused with a polyhistidine tag at the C-terminus.

Source:

Human

Expression Host:

Human Cells

ACVR2B Protein QC Testing

Purity:

﹥97 % as determined by SDS-PAGE.

SDS-PAGE:

Endotoxin:

< 1.0 EU per 1μg of the protein as determined by the LAL method.

Stability:

Samples are stable for up to twelve months from date of receipt at -70℃

Predicted N terminal:

Ser 19

Molecular Mass:

The recombinant human ACVR2B comprises 127 amino acids and predicts a molecular mass of 15 KDa. As a result of glycosylation, rh ACVR2B migrates as an approximately 33-38 KDa protein in SDS-PAGE under reducing conditions.

Formulation:

Supplied as a 0.2μm filtered solution of PBS, pH7.4

ACVR2B Protein Usage Guide

Storage:

Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted and be used as soon as possible.; Avoid repeated freeze-thaw cycles

Reconstitution:

Follow the instructions on the vial. Centrifuge the vial at 4℃ before opening to recover the entire contents.

ACVR2B Protein Description

Activin isoforms are dimeric growth and differentiation factors which belong to the transforming growth factor-beta (TGF-β) superfamily of structurally related signaling proteins. Activins exert their biological actions by binding to heteromeric receptor complexes consisting of at least two type I (I and IB) and two type II (II and IIB) receptor. These Activin receptors are all transmembrane proteins, composed of a ligand-binding extracellular domain with cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with predicted serine/threonine kinase activity. Type I receptors are essential for signal transduction and type II receptors are required for ligand binding and the expression of type I receptors. On ligand binding, Type I and II receptors form a stable complex, resulting in phosphorylation of type I receptors by type II receptors with constitutive kinase activity, and subsequently the activation of downstream molecules including the endogenous Smads is initiated. This protein, activin A type IIB receptor, displays a 3- to 4-fold higher affinity for the ligand than activin A type II receptor.